[go: up one dir, main page]

PE20121690A1 - Signatura transcripcional en la sangre de infecciones de mycobacterium tuberculosis activas versus latentes - Google Patents

Signatura transcripcional en la sangre de infecciones de mycobacterium tuberculosis activas versus latentes

Info

Publication number
PE20121690A1
PE20121690A1 PE2012000735A PE2012000735A PE20121690A1 PE 20121690 A1 PE20121690 A1 PE 20121690A1 PE 2012000735 A PE2012000735 A PE 2012000735A PE 2012000735 A PE2012000735 A PE 2012000735A PE 20121690 A1 PE20121690 A1 PE 20121690A1
Authority
PE
Peru
Prior art keywords
blood
infection
latent tuberculosis
tuberculosis mycobacterium
active versus
Prior art date
Application number
PE2012000735A
Other languages
English (en)
Inventor
Jacques F Banchereau
Damien Chaussabel
Anne O'garra
Matthew Berry
Onn Min Kon
Original Assignee
Baylor Res Inst
Medical Res Council
Imp College Healthcare Nhs Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst, Medical Res Council, Imp College Healthcare Nhs Trust filed Critical Baylor Res Inst
Publication of PE20121690A1 publication Critical patent/PE20121690A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

SE REFIERE A UN METODO PARA DETECTAR UNA INFECCION ACTIVA POR MYCOBACTERIUM TUBERCULOSIS QUE ESTA LATENTE Y ASINTOMATICA QUE COMPRENDE A) OBTENER UN CONJUNTO DE DATOS DE LA EXPRESION GENETICA DE PACIENTES CON UNA INFECCION LATENTE Y ASINTOMATICA POR MYCOBACTERIUM TUBERCULOSIS; B) CLASIFICAR EL CONJUNTO DE DATOS DE LA EXPRESION GENETICA OBTENIDO EN EL PASO (A) EN MODULOS GENETICOS ASOCIADOS CON UNA INFECCION POR MYCOBACTERIUM TUBERCULOSIS; C) COMPARAR EL CONJUNTO DE DATOS DE LA EXPRESION GENETICA DE UN PACIENTE NO CLASIFICADO CON LOS MODULOS GENETICOS DESCRITOS EN (B), EN DONDE UN INCREMENTO O DISMINUCION EN LA TOTALIDAD DE LA EXPRESION GENETICA INDICA UNA INFECCION ACTIVA POR MYCOBACTERIUM TUBERCULOSIS EN LUGAR DE UNA INFECCION LATENTE Y ASINTOMATICA
PE2012000735A 2009-11-30 2010-08-19 Signatura transcripcional en la sangre de infecciones de mycobacterium tuberculosis activas versus latentes PE20121690A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/628,148 US20110129817A1 (en) 2009-11-30 2009-11-30 Blood transcriptional signature of active versus latent mycobacterium tuberculosis infection

Publications (1)

Publication Number Publication Date
PE20121690A1 true PE20121690A1 (es) 2012-12-16

Family

ID=44067161

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000735A PE20121690A1 (es) 2009-11-30 2010-08-19 Signatura transcripcional en la sangre de infecciones de mycobacterium tuberculosis activas versus latentes

Country Status (20)

Country Link
US (2) US20110129817A1 (es)
EP (1) EP2519652A4 (es)
JP (1) JP2013511981A (es)
KR (2) KR20140078768A (es)
CN (1) CN102844444A (es)
AP (1) AP2012006346A0 (es)
AR (1) AR080570A1 (es)
AU (1) AU2010325179B2 (es)
BR (1) BR112012013029A2 (es)
CA (1) CA2782211A1 (es)
CL (1) CL2012001400A1 (es)
EA (1) EA201270650A1 (es)
IL (1) IL220016A0 (es)
MX (1) MX2012006031A (es)
PE (1) PE20121690A1 (es)
PH (1) PH12012501043A1 (es)
SG (1) SG10201407855WA (es)
TW (1) TW201131032A (es)
WO (1) WO2011066008A2 (es)
ZA (1) ZA201204806B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524966A1 (en) * 2011-05-18 2012-11-21 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of tuberculosis
TWI458978B (zh) * 2011-12-27 2014-11-01 Chengchung Chou 判別開放性或潛伏性結核菌感染之方法
WO2013138497A1 (en) * 2012-03-13 2013-09-19 Baylor Research Institute Early detection of tuberculosis treatment response
EP2836608A4 (en) 2012-04-13 2016-02-24 Somalogic Inc TUBERCULOSIS BIOMARKERS AND USES THEREOF
GB201211158D0 (en) * 2012-06-22 2012-08-08 Univ Nottingham Trent Biomarkers and uses thereof
US20150284780A1 (en) * 2012-10-30 2015-10-08 Imperial Innovations Limited Method of detecting active tuberculosis in children in the presence of a co-morbidity
US20150315643A1 (en) * 2012-12-13 2015-11-05 Baylor Research Institute Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
EP2962100B1 (en) 2013-02-28 2021-07-28 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof
GB201315748D0 (en) 2013-09-04 2013-10-16 Imp Innovations Ltd Biological methods and materials for use therein
WO2015048098A1 (en) 2013-09-24 2015-04-02 Washington University Diagnostic methods for infectious disease using endogenous gene expression
EP3132270A4 (en) * 2014-04-15 2017-09-13 Stellenbosch University A method for diagnosing tuberculous meningitis
CN103954755B (zh) * 2014-04-30 2017-04-05 广东省结核病控制中心 一种结核分枝杆菌潜伏感染的诊断试剂盒
US10041945B2 (en) 2014-05-05 2018-08-07 Emory University Methods of diagnosing and treating tuberculosis
ES2857000T3 (es) * 2015-10-14 2021-09-28 Univ Leland Stanford Junior Métodos para el diagnóstico de la tuberculosis
GB201519872D0 (en) * 2015-11-11 2015-12-23 Univ Cape Town And Ct For Infectious Disease Res Biomarkers for prospective determination of risk for development of active tuberculosis
GB2547034A (en) * 2016-02-05 2017-08-09 Imp Innovations Ltd Biological methods and materials for use therein
KR101888101B1 (ko) * 2016-09-19 2018-08-14 충남대학교산학협력단 Scotin 단백질의 과발현에 의하여 결핵균 생존 및 증식을 억제하는 방법
JP6306124B2 (ja) * 2016-11-01 2018-04-04 国立大学法人高知大学 結核検査用バイオマーカー
CN107653313B (zh) * 2017-09-12 2021-07-09 首都医科大学附属北京胸科医院 Retn和klk1在作为结核病检测标志物中的应用
US11443433B2 (en) * 2018-02-10 2022-09-13 The Trustees Of The University Of Pennsylvania Quantification and staging of body-wide tissue composition and of abnormal states on medical images via automatic anatomy recognition
GB201804019D0 (en) * 2018-03-13 2018-04-25 Univ Cape Town Method for predicting progression to active tuberculosis disease
US11036779B2 (en) * 2018-04-23 2021-06-15 Verso Biosciences, Inc. Data analytics systems and methods
CN109061191B (zh) * 2018-08-23 2021-08-24 中国人民解放军第三〇九医院 S100p蛋白作为标志物在诊断活动性结核病中的应用
CN108828235A (zh) * 2018-08-23 2018-11-16 中国人民解放军第三〇九医院 Pglyrp1蛋白作为标志物在诊断活动性结核病中的应用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN110286231A (zh) * 2019-06-19 2019-09-27 中国人民解放军总医院第八医学中心 用于检测cd160蛋白的物质在制备用于诊断活动性结核病的产品中的应用
CN111304313A (zh) * 2019-12-13 2020-06-19 南方医科大学 一种检测fpr1基因表达水平的试剂的应用
EP3868894A1 (en) * 2020-02-21 2021-08-25 Forschungszentrum Borstel, Leibniz Lungenzentrum Method for diagnosis and treatment monitoring and individual therapy end decision in tuberculosis infection
WO2024119057A2 (en) * 2022-12-02 2024-06-06 Cornell University Plasma cell-free rna signatures of tuberculosis
CN116994646B (zh) * 2023-08-01 2024-06-11 东莞市滨海湾中心医院(东莞市太平人民医院、东莞市第五人民医院) 一种菌阳活动性肺结核风险评估模型的构建方法与应用
CN119044484B (zh) * 2024-09-02 2025-01-21 中国科学院微生物研究所 活动性肺结核诊断及鉴别诊断标志物组合及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627198B2 (en) * 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
US6713257B2 (en) * 2000-08-25 2004-03-30 Rosetta Inpharmatics Llc Gene discovery using microarrays
AU2002241520A1 (en) * 2000-11-28 2003-03-03 University Of Cincinnati Blood assessment of injury
AU2002314358C1 (en) * 2001-07-04 2009-03-26 The Secretary Of State For Health Mycobacterial antigens expressed during latency
WO2004001070A1 (en) * 2002-06-20 2003-12-31 Glaxo Group Limited Surrogate markers for the determination of the disease status of an individual infected by mycobacterium tuberculosis
AP2011005546A0 (en) * 2008-06-25 2011-02-28 Baylor Res Intitute Blood transcriptional signature of mycobacterium tuberculosis infection.

Also Published As

Publication number Publication date
CL2012001400A1 (es) 2014-05-09
JP2013511981A (ja) 2013-04-11
EP2519652A4 (en) 2013-05-01
MX2012006031A (es) 2012-10-03
ZA201204806B (en) 2013-02-27
KR20140078768A (ko) 2014-06-25
AP2012006346A0 (en) 2012-06-30
US20110129817A1 (en) 2011-06-02
EP2519652A2 (en) 2012-11-07
CN102844444A (zh) 2012-12-26
TW201131032A (en) 2011-09-16
IL220016A0 (en) 2012-07-31
AR080570A1 (es) 2012-04-18
WO2011066008A2 (en) 2011-06-03
PH12012501043A1 (en) 2013-02-04
AU2010325179A1 (en) 2012-07-05
BR112012013029A2 (pt) 2016-10-04
KR20120107979A (ko) 2012-10-04
WO2011066008A3 (en) 2011-07-21
AU2010325179B2 (en) 2015-03-12
US20140080732A1 (en) 2014-03-20
CA2782211A1 (en) 2011-06-03
SG10201407855WA (en) 2015-01-29
EA201270650A1 (ru) 2013-06-28

Similar Documents

Publication Publication Date Title
PE20121690A1 (es) Signatura transcripcional en la sangre de infecciones de mycobacterium tuberculosis activas versus latentes
BR112017017876A2 (pt) sensores de impressão digital para dispositivos móveis
BR112014029588A2 (pt) sistema e métodos para detectar distúrbios de saúde
CO6551725A2 (es) Dispositivo para la identificación de afecciones orales
BR112015009223A2 (pt) dispositivo e método de processamento de informação, mídia legível por computador não temporária, e, aparelho de exibição
EA201170088A1 (ru) Транскрипционная сигнатура крови инфекции mycobacterium tuberculosis
ATE471691T1 (de) Optische bildmessvorrichtung und bildverarbeitungsvorrichtung
UA109271C2 (uk) Комбінація фітоканабіноїдів та темозоламіду для лікування гліоми
BR112016024187A2 (pt) sistema sensor de fibra óptica, e, método para a determinação de uma localização de uma perturbação
MX356802B (es) Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf.
ECSP13012431A (es) Combinación del compuesto glyt1 con antipsicóticos
BR112012020251A2 (pt) dispositivo de análise para a aquisição de amostra, tratamento e reação
BR112013010283A2 (pt) método de calibração de um sensor de ar de um dispositivo de tratamento de ar, conjunto de instruções executáveis por computador e dispositivo de tratamento de ar
BR112015009056A2 (pt) aparelho e método para calcular um valor de estimativa de risco de trombose de um paciente com base em características de entrada específicas do paciente, e, produto de programa de computador
BR112018008905A8 (pt) método, e sistema
ES2811835T3 (es) Procedimiento para determinar el riesgo de toxicidad por 5-fluorouracilo
MX2017012470A (es) Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico.
CL2018001804A1 (es) Uso de la carrimicina en la infección por micobacterium tuberculosis resistente
MX376874B (es) Beta-caseina a2 y niveles de glucosa en sangre.
BR112018006393A2 (pt) método para classificar um linfoma difuso de grande célula b (dlbcl), uma ou mais mídias de armazenamento legíveis por computador, sistema de computação adaptado e kit
MX2020003662A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero hibrido acrilico de silicona.
BR112015027140A8 (pt) Módulo de cálculo de bloqueio e método de cálculo de bloqueio
DOP2012000316A (es) Metodo para diagnosticar una respuesta al tratamiento en sujetos con esclerosis multiple
CO6321268A2 (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
BR112013005518A2 (pt) método para detectar anticorpos específicos de vírus em uma amostra, método para diagnosticar uma infecção viral, método para aumentar os baixos níveis de anticorpos antivirais em uma amostra de sangue complera e kit para a detecção de anticorpos especificos de vírus expressos em níveis baixos em um indivíduo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal